Homology lays off staff, pauses rare metabolic disease trial despite clinical hold lift

Paul Schloesser

Associate Editor

Despite getting the all-clear from the FDA to restart a clinical trial, a biotech is instead pausing enrollment and dosing to refocus on another candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Homology lays off staff, pauses rare metabolic disease trial despite clinical hold lift

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ho­mol­o­gy lays off staff, paus­es rare meta­bol­ic dis­ease tri­al de­spite clin­i­cal hold lift

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Homology lays off staff, pauses rare metabolic disease trial despite clinical hold lift